{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:54:57Z","timestamp":1784876097535,"version":"3.55.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to examine the role of computed tomography (CT)-derived myosteatosis, sarcopenia, and other body composition parameters on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to receive lutetium (Lu)-177 treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and method<\/jats:title>\n                    <jats:p>\n                      Patients with mCRPC who underwent\n                      <jats:sup>68<\/jats:sup>\n                      Ga-prostate-specific membrane antigen (PSMA) PET\/CT imaging before [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-PSMA-617 treatment and received at least two cycles of Lu-177 PSMA treatment between March 2017 and March 2023 were retrospectively reviewed in this study. Body composition including psoas muscle, skeletal muscle, subcutaneous adipose tissue, and visceral adipose tissue were evaluated at the third lumbar spine vertebra on CT axial sections.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median age of the 76 patients enrolled in this study was 75\u2005years (59\u201391\u2005years), and the median Gleason score was 8 (6\u201310). All patients received two to six (median 4) cycles of 7.4\u2005GBq Lu-177 PSMA treatment at 6\u20138\u2005week intervals. Upon univariant Cox regression analysis, subcutaneous adipose tissue index, right psoas myosteatosis, left psoas myosteatosis, and skeletal muscle index were determined to be prognostic factors for OS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.03,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001, and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.04, respectively). However, the left psoas myosteatosis value was an independent prognostic factor for OS as determined by multivariant Cox regression analysis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sarcopenia and myosteatosis before treatment were associated with shorter survival in mCRPC patients who were scheduled for Lu-177 PSMA treatment. Patients with left psoas myosteatosis value \u226426.85\u2005HU had shorter OS, and we showed that OS is an independent prognostic factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000001985","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:31:14Z","timestamp":1746070274000},"page":"592-598","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effect of body composition parameters, including sarcopenia, myosteatosis, and adipose tissue, on overall survival of patients with mCRPC receiving 177Lu-PSMA PRRT"],"prefix":"10.1097","volume":"46","author":[{"given":"\u0130hsan","family":"Kaplan","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"K\u00f6mek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulya","family":"Kaya \u0130pek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferat","family":"Kepenek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"Karao\u011flan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayhan","family":"\u015eenol","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"G\u00fczel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysi","family":"\u015eenses","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridvan","family":"Kili\u00e7","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"Yeprem","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Serdar","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgin Bahadir","family":"Ba\u015fg\u00f6z","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"G\u00fczel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"R1-20251022","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20251022","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4045\/tidsskr.16.0265","article-title":"Modern treatment of metastatic prostate cancer.","volume":"137","author":"Holm","year":"2017","journal-title":"Tidsskr Nor Laegeforen"},{"key":"R3-20251022","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology.","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"key":"R4-20251022","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2967\/jnumed.119.234054","article-title":"Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III vision trial and its importance for the future of theranostics.","volume":"60","author":"Rahbar","year":"2019","journal-title":"J Nucl Med"},{"key":"R5-20251022","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.juro.2007.07.026","article-title":"Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.","volume":"178","author":"Montgomery","year":"2007","journal-title":"J Urol"},{"key":"R6-20251022","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis.","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"R7-20251022","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/apha.12224","article-title":"Measurement of skeletal muscle radiation attenuation and basis of its biological variation.","volume":"210","author":"Aubrey","year":"2014","journal-title":"Acta Physiol (Oxf)"},{"key":"R8-20251022","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/JU.0000000000001428","article-title":"Obesity is associated with longer survival independent of sarcopenia and myosteatosis in metastatic and\/or castrate-resistant prostate cancer.","volume":"205","author":"Xu","year":"2021","journal-title":"J Urol"},{"key":"R9-20251022","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus.","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R10-20251022","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12877-016-0349-4","article-title":"Sarcopenia in daily practice: assessment and management.","volume":"16","author":"Beaudart","year":"2016","journal-title":"BMC Geriatr"},{"key":"R11-20251022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","article-title":"Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy.","volume":"7","author":"Ohtaka","year":"2019","journal-title":"Prostate Int"},{"key":"R12-20251022","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/j.clgc.2023.01.009","article-title":"Sarcopenia in men with bone-predominant metastatic castration-resistant prostate cancer undergoing Ra-223 therapy.","volume":"21","author":"Khan","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"R13-20251022","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2967\/jnumed.122.265379","article-title":"Elevated body mass index is associated with improved overall survival in castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen-directed radioligand therapy.","volume":"64","author":"Hartrampf","year":"2023","journal-title":"J Nucl Med"},{"key":"R14-20251022","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"R15-20251022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12893-024-02457-5","article-title":"Associations of body composition parameters with postoperative outcome and perineural tumour invasion after oncological pancreatic resection.","volume":"24","author":"Mueller","year":"2024","journal-title":"BMC Surg"},{"key":"R16-20251022","doi-asserted-by":"crossref","first-page":"101113","DOI":"10.1016\/j.jhepr.2024.101113","article-title":"Sarcopenia evaluated by EASL\/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: a systematic review and meta-analysis.","volume":"6","author":"Dajti","year":"2024","journal-title":"JHEP Rep"},{"key":"R17-20251022","doi-asserted-by":"crossref","first-page":"9242243","DOI":"10.1155\/2022\/9242243","article-title":"Clinical features and body composition in men with hormone-sensitive metastatic prostate cancer: a pilot study examining differences by race.","volume":"2022","author":"Sheean","year":"2022","journal-title":"Prostate Cancer"},{"key":"R18-20251022","doi-asserted-by":"crossref","first-page":"e17213","DOI":"10.1097\/MD.0000000000017213","article-title":"Prognostic value of radiologically determined sarcopenia prior to treatment in urologic tumors: a meta-analysis.","volume":"98","author":"Li","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R19-20251022","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","article-title":"Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.","volume":"13","author":"Cushen","year":"2016","journal-title":"Clin Nutr ESPEN"},{"key":"R20-20251022","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41391-021-00442-0","article-title":"Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis.","volume":"25","author":"Lopez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R21-20251022","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.ejca.2015.07.042","article-title":"High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.","volume":"51","author":"Antoun","year":"2015","journal-title":"Eur J Cancer"},{"key":"R22-20251022","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/nu15071631","article-title":"Androgen deprivation therapy for prostate cancer influences body composition increasing risk of sarcopenia.","volume":"15","author":"Korczak","year":"2023","journal-title":"Nutrients"},{"key":"R23-20251022","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R24-20251022","doi-asserted-by":"crossref","first-page":"101398","DOI":"10.1016\/j.arr.2021.101398","article-title":"Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia.","volume":"70","author":"Ahn","year":"2021","journal-title":"Ageing Res Rev"},{"key":"R25-20251022","doi-asserted-by":"crossref","first-page":"102839","DOI":"10.1016\/j.critrevonc.2019.102839","article-title":"Myosteatosis and prognosis in cancer: systematic review and meta-analysis.","volume":"145","author":"Aleixo","year":"2020","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:00:16Z","timestamp":1761120016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001985","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}